Research

Impact of Socioeconomic Disparities and Facility Type on Overall Survival in Stage I vs Stage IV Amelanotic Melanoma: An Analysis of the National Cancer Database


 

PURPOSE

This study addresses a gap in knowledge regarding socioeconomic factors, facility type, and overall survival in stage I vs stage IV Amelanotic Melanoma.

BACKGROUND

Amelanotic Melanoma (AM) is a rare form of melanoma that lacks pigment and accounts for approximately 5% of melanomas. Light skin color and increasing age are important risk factors. Although curable when diagnosed early, it is often missed or mistaken for other benign conditions. A study investigating the impact of facility type on overall survival between stage I vs stage IV AM has yet to be done.

METHODS

This is a retrospective study of patients diagnosed with Amelanotic Melanoma (ICD-8730) between 2004 and 2020 in the National Cancer Database (NCDB) to compare demographic features and overall survival (n = 2147). Exclusion criteria included missing data.

DATA ANALYSIS

Descriptive statistics for all AM patients were collected. Median household income and facility type were compared between patients diagnosed with stage I and stage IV AM using Pearson Chi- Square test. Breslow thickness and overall survival between stage I and stage IV were evaluated using independent t-test and Kaplan-Meier test, respectively. All variables were evaluated for a significance of P < .05.

RESULTS

Most cases analyzed were White (98.1%), male (58.6%), and had Medicare as the primary payor at diagnosis (51.1%). Of 2147 cases, 497 were stage I (23.1%) and 164 were stage IV AM (7.6%) with a mean age at diagnosis of 66.05 and 63.72 years, respectively. There was a significant difference in overall survival between stage I (mean = 118.7 months) and stage 4 (mean = 42.4 months, P < 0.001). The average Breslow thickness was 1.17mm in stage I and 2.59mm in stage IV (P<0.05). More patients diagnosed at stage I used academic facilities than those diagnosed at stage IV (43.9% vs 33.8%, P<0.05). Most patients diagnosed at stage I were high income compared to patients diagnosed at stage IV (55% vs 43.2%, P<0.05).

CONCLUSIONS

With the overall survival of stage IV AM being significantly worse, we hope this study can provide a starting point in the study and prevention of disparities in the early diagnosis of AM.

Recommended Reading

Cancer Data Trends 2023
Federal Practitioner
Necessary Updates to Skin Cancer Risk Stratification
Federal Practitioner
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
Federal Practitioner
CBSM phone app eases anxiety, depression in cancer patients
Federal Practitioner
Multiprong strategy makes clinical trials less White
Federal Practitioner
Imaging techniques will revolutionize cancer detection, expert predicts
Federal Practitioner
No benefit to adding limited radiation in advanced cancer
Federal Practitioner
RFS failed as endpoint in adjuvant immunotherapy trials
Federal Practitioner
Do AI chatbots give reliable answers on cancer? Yes and no
Federal Practitioner
Clinical Impact of UV Mutational Signatures in Veterans With Cancer
Federal Practitioner